# Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma

> **NCT07097207** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shenzhen University General Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Relapsed/Refractory B-cell Lymphoma

## Interventions

- **COMBINATION_PRODUCT:** CAR-T cell

## Key facts

- **NCT ID:** NCT07097207
- **Lead sponsor:** Shenzhen University General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-01
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07097207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07097207, "Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07097207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*